newsfilter
← Latest News
Business Wire·

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran Company Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track